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Abstract Neoadjuvant chemotherapy trials have consis-
tently reported lower response rates in hormone receptor-
positive (HR+) breast cancer when compared with
HR– cases. Preoperative endocrine therapy has therefore
become a logical alternative and has gained considerable
momentum from the ﬁnding that aromatase inhibitors (AIs)
are more effective than tamoxifen for HR+ breast cancer in
both the neoadjuvant and adjuvant settings. The most
convincing neoadjuvant trial to demonstrate the superiority
of an AI versus tamoxifen was the P024 study, a large
multinational double-blind trial in postmenopausal women
with HR+ breast cancer ineligible for breast-conserving
surgery. The overall response rate (ORR) was 55% for
letrozole and 36% for tamoxifen (P\0.001). Signiﬁcantly
more letrozole-treated patients underwent breast-conserv-
ing surgery (45 vs. 35%, respectively; P = 0.022). In
addition, ORR was signiﬁcantly higher with letrozole than
tamoxifen in the human epidermal growth factor receptor
HER1/HER2+ subgroup (P = 0.0004). The clinical efﬁ-
cacy of letrozole in HER2+ breast cancer was conﬁrmed by
ﬂuorescent in situ hybridization analysis and was found to
be comparable to that of HER2– cases (ORR 71% in both
subsets). Biomarker studies conﬁrmed the superiority of
letrozole in centrally assessed estrogen receptor-positive
(ER+) tumors and found a strong relationship with the
degree of ER positivity for both agents. Interestingly, le-
trozole was effective even in marginally ER+ tumors and,
unlike tamoxifen, consistently reduced the expression
from estrogen-regulated genes (progesterone receptor and
trefoil factor 1). Furthermore, when analyzed by Ki67
immunohistochemistry, letrozole was signiﬁcantly more
effective than tamoxifen in reducing tumor proliferation
(P = 0.0009). Thus, neoadjuvant letrozole is safe and
superior to tamoxifen in the treatment of postmenopausal
women with HR+ locally advanced breast cancer.
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Introduction and rationale
Early-stage breast cancer is traditionally treated with an
initial surgery such as lumpectomy or mastectomy
followed by subsequent adjuvant therapy, including
radiotherapy, chemotherapy, and hormone therapy [1, 2].
Numerous studies have investigated the use of preoperative
(neoadjuvant) hormonal therapy or chemotherapy prior to
surgical intervention, with the goals to improve surgical
outcome and obtain long-term disease-free survival (DFS)
(see Table 1). The National Surgical Adjuvant Breast and
Bowel Project B-18 trial demonstrated that doxorubicin
and cyclophosphamide administered as neoadjuvant or
adjuvant therapy had equivalent outcomes in terms of both
DFS and overall survival (OS) [3]. Adding a taxane in the
B-27 trial signiﬁcantly reduced the local recurrence rate but
did not signiﬁcantly increase DFS or OS [4]. Importantly,
neoadjuvant chemotherapy has been shown to increase the
rate of breast-conserving surgery (BCS) without adversely
affecting DFS or OS [3, 5–7]. Therefore, neoadjuvant
chemotherapy has become the standard treatment approach
for locally advanced breast cancer and an accepted option
for patients with primary operable disease [8].
M. J. Ellis (&)  C. Ma
Medical Oncology, Washington University, Campus Box 8056,
660 Euclid Ave, St Louis, MO 63110, USA
e-mail: mellis@wustl.edu
123
Breast Cancer Res Treat (2007) 105:33–43
DOI 10.1007/s10549-007-9701-xSigniﬁcant tumor reduction from neoadjuvant chemo-
therapy occurs in only subsets of breast cancer, however.
For example, patients with estrogen receptor-negative
(ER–), high-grade, and highly proliferative tumors appear
to beneﬁt the most from neoadjuvant chemotherapy [9–11].
In contrast, signiﬁcantly lower response rates have been
reported in patients with ER+ tumors in neoadjuvant che-
motherapy trials [12–15]. The German Breast Group
demonstrated that the pathologic complete response (pCR)
rates were 6.2 versus 22.8% for ER+ and ER– tumors,
respectively (odds ratio 3.23, 95% conﬁdence intervals
[CIs] 1.91, 5.46; P = 0.0001) [12]. Recent studies indicate
that the sensitivity to chemotherapy is likely determined by
the underlying gene expression pattern and the molecular
subtype of the tumor [16, 17]. The luminal subtype cate-
gorized by gene expression proﬁling, which encompasses
most of the ER+ tumors, is less responsive to preoperative
chemotherapy than the basal-like and human epidermal
growth factor receptor 2-positive (HER2+) cancer. In
addition, neoadjuvant chemotherapy is associated with
substantial toxicity that may limit its clinical beneﬁts and
acceptability, especially in the elderly patient population
[13, 18–20]. Thus, there is great need for effective alter-
natives to cytotoxic chemotherapy in hormone-responsive
locally advanced breast cancer.
Endocrine treatment is an attractive alternative to che-
motherapy as neoadjuvant or primary systemic therapy for
women with hormone-responsive primary breast tumors
[21–23]. A study comparing neoadjuvant endocrine ther-
apy with exemestane versus chemotherapy in 152 patients
with ER+/progesterone receptor-positive (PgR+) breast
cancer found that while efﬁcacy outcomes were compara-
ble in the two groups, chemotherapy treatment was
signiﬁcantly more toxic, conﬁrming that endocrine therapy
could be used as an alternative to chemotherapy in older
women [24]. Early studies of primary tamoxifen as an
alternative to surgery were conducted in older women with
hormone-responsive breast cancer who were unﬁt for
chemotherapy [23, 25–27]. While these studies demon-
strated a reduction in tumor size with primary tamoxifen,
long-term local disease control was found to be poor. The
omission of primary surgery resulted in an increased rate of
progression, therapeutic intervention, and mortality [28].
Thus, primary tamoxifen treatment is indicated for only the
most frail, medically ill, or noncompliant patients [29].
Although primary therapy with tamoxifen was found to be
well-tolerated, adverse effects were reported including hot
ﬂushes, skin rash, vaginal discharge, breast pain, sleepi-
ness, headache, vertigo, itching, hair loss, cystitis, acute
thrombophlebitis, nausea, and indigestion [29]. Further-
more, more serious adverse effects, such as an increased
risk of endometrial cancer and thromboembolic events,
have been reported in large trials of adjuvant tamoxifen
[30].
In view of the limitations of tamoxifen as a single
modality treatment, attention has switched to the neoad-
juvant use of endocrine therapy to increase the rate of
breast conservation [21]. Data from preclinical models [31]
and clinical studies in advanced breast cancer [32] predict
that aromatase inhibitors (AIs) may be more effective than
tamoxifen in the neoadjuvant setting. Furthermore, pre-
clinical and clinical evidence suggests that letrozole may
be the most effective AI in this setting [33–35]. In post-
menopausal women with endocrine-responsive locally
advanced or metastatic breast cancer, ﬁrst-line treatment
with letrozole was shown to be signiﬁcantly more effective
than tamoxifen in terms of response rate (overall response
rate [ORR], 30 vs. 20%, P = 0.0006) and time to disease
progression (41 vs. 26 weeks) [32]. A phase 1–2 pilot study
showed a clinical response rate of 88% (21/24 patients) in
postmenopausal women with ER+ locally advanced breast
cancer treated with letrozole for 3 months prior to surgery
[36]. All patients in the study were eligible for breast
conserving surgery following neoadjuvant letrozole.
Table 1 Aims of neoadjuvant therapy in different breast cancer populations
Population Aims Treatment option
Locally advanced breast cancer Primary: to improve surgical options Fit and healthy patients: chemotherapy
Secondary: to obtain freedom from disease,
to gain information on tumor response
Unﬁt patients with hormone-sensitive
disease: endocrine treatment
Operable breast cancer and candidates for
adjuvant chemotherapy
Primary: to obtain freedom from disease Chemotherapy ± OFS and/or AIs
Secondary: to improve surgical options,
to gain information on tumor response
Sequence versus combination
Longer versus shorter
Operable breast cancer and candidates for
adjuvant endocrine treatment alone
Primary: to improve surgical options Endocrine treatment longer versus shorter
Secondary: to gain information on tumor response Tamoxifen versus AIs
Reprinted from [8] with permission from
the American Society of Clinical Oncology
AIs aromatase inhibitors, NST neoadjuvant systemic therapy, OFS ovarian function suppression
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the efﬁcacy of neoadjuvant letrozole compared with
tamoxifen in postmenopausal women with hormone
receptor-positive (HR+) breast cancer who were ineligible
for breast-conserving surgery [21]. The clinical objectives
of the trial were to compare response rates and surgical
outcomes between the two treatment arms. In addition, the
trial provided the opportunity to conduct prospective bio-
marker studies to explore the biologic basis for response to
neoadjuvant endocrine therapy [37]. This review describes
the results of the P024 study and the follow-up biomarker
studies, focusing on the treatment implications in the
neoadjuvant setting.
Trial design and patients
PO24 was a multinational, randomized, double-blind con-
trolled trial comparing letrozole and tamoxifen in
postmenopausal women with hormone-responsive primary
invasive breast cancer who were not eligible for breast-
conserving surgery [21]. The trial was conducted in 55
centers in 16 countries between March 1998 and August
1999. Local ethics review boards approved the protocol
and all patients gave written informed consent before study
enrollment.
Randomized clinical trial design
Patients were randomly assigned to receive letrozole
2.5 mg or tamoxifen 20 mg administered orally once daily
for 4 months prior to scheduled surgery [21]. Patients were
considered to have completed the study when they had
received 4 months of treatment and had been assessed for
surgery. Following surgery, patients were treated at the
investigator’s discretion and were followed for 5 years for
local recurrence, distant metastasis, and survival.
Patient population
A total of 337 postmenopausal women were enrolled into
the trial, and 324 were included in the intent-to-treat pop-
ulation (see Fig. 1). Eligible patients were postmenopausal
women with untreated, primary HR+ (‡10% nuclear
staining for ER or PgR) invasive breast tumors (stages T2–
4a–c, N0–2, M0). The minimum tumor size was ‡3 cm,
and all patients were considered inoperable or ineligible for
breast-conserving surgery, mostly because of a non-favor-
able ratio tumor size/breast size. Exclusion criteria
included previous exposure to AIs, uncontrolled endocrine
or cardiac disease, bilateral or inﬂammatory breast cancer,
distant metastasis, and other malignant disease. In addition,
administration of other cancer treatment or hormone
replacement therapy was not allowed during study
participation.
Trial end points
The primary end point was ORR, deﬁned as the percentage
of patients in each treatment arm with a complete response
(CR) or a partial response (PR) as determined by breast
Fig. 1 Patient disposition [21]
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123palpation [21]. Response categories were CR, PR, no
change, progressive disease, or not assessable/not evalu-
able. The secondary end points were the percentage of
patients who underwent breast-conserving surgery and
the response rate (CR + PR) determined at 4 months by
mammography and by ultrasound [21]. Safety was assessed
and adverse events graded according to the National
Cancer Institute Common Toxicity Criteria.
Correlative science studies
In parallel, studies were conducted in which tumor biopsies
and blood samples were taken from all patients prior to the
initiation of therapy and at the end of treatment to generate
a database from which changes in molecular markers could
be assessed [37–41]. These studies were prospectively
designed to assess the biological basis for letrozole efﬁ-
cacy. The speciﬁc objectives of the biomarker sub-studies
were as follows:
1. ToconﬁrmERandPgRstatusinacentrallaboratory.ER
and PgR were determined using immunohistochemistry
(IHC) performed on pretreatment biopsies; the criterion
for minimal ER positivity was 10% positive cells [37].
The Allred histopathological score was applied to
further assess the level of ER and PgR expression in
both the baseline and surgical specimens [42].
2. To explore relationships between ER and PgR expres-
sion levels and response to treatment [37].
3. To examine the relationship between the expression of
HER1 and HER2 and the likelihood of primary
response [37]. Previous studies have shown that
HER2 overexpression may be a predictor of tamoxifen
resistance [43, 44], and HER1 has also been linked with
endocrine therapy resistance [45]. HER2 IHC was
initially scored as 0/+ (negative) or ++/+++ (positive or
overexpressed) [46]. Since ﬂuorescent in situ hybrid-
ization (FISH) testing has replaced IHC as the gold
standard for HER2 assessment, the P024 tumor bank
was reassessed using HER1 and HER2 FISH probes,
and these data on HER2 gene ampliﬁcation status were
supplemented with 106 tumor samples [40]. Pre- and
post-treatment tumor biopsy samples were also ana-
lyzed for ER and several indices of ER function,
including PgR and trefoil factor 1 (TFF1), HER1 and
HER2, and the proliferation marker Ki67 [38].
4. To assess gene expression proﬁling as a means to
further investigate the transcriptional programs that
underlie resistance and sensitivity to estrogen depri-
vation [39]. Gene expression (mRNA) proﬁles were
collected from the tumor biopsies collected prior to
surgery, at 1 month of treatment, and at surgery. The
analysis was done using an Affymetrix U 133 subA
Gene Chip.
5. To measure aromatase expression in tumors before and
after 4 months of letrozole or tamoxifen treatment.
Aromatase is the key enzyme responsible for estrogen
biosynthesis and is present in about 70% of tumors.
IHC was performed with a monoclonal aromatase
antibody (677) on trial samples prior to and following
letrozole or tamoxifen treatment (n = 185); scoring
was measured as a proportion of immuno-positive cells
and their intensity of reactivity in malignant epithelial,
stromal, adipose, and normal compartments [41].
Efﬁcacy
In the intent-to-treat population, 154 patients received le-
trozole and 170 received tamoxifen. Similar proportions of
patients in the letrozole and tamoxifen groups had inop-
erable tumors (13 and 14%, respectively). Other baseline
characteristics were also well-balanced for age, race, HR
status, and tumor/nodal stage of disease. More patients in
the tamoxifen group (n = 41) discontinued treatment than
in the letrozole arm (n = 23). The main reason for pre-
mature discontinuation was disease progression.
Clinical response and breast-conserving surgery
Letrozole was consistently superior to tamoxifen for pri-
mary and secondary efﬁcacy end points [21]. The ORR was
55% for letrozole versus 36% for tamoxifen (P\0.001).
Median time to response was 66 days in the letrozole group
and 70 days in the tamoxifen group. The odds ratio for
achieving CR + PR was more than doubled with letrozole
(2.23, 95% CI 1.43, 3.50; P = 0.0005). In terms of clinical
progression, 12% of patients on letrozole and 17% on
tamoxifen progressed, while 24% of letrozole- and 35% of
tamoxifen-treated patients had stable disease. Letrozole
was also shown to be signiﬁcantly more effective than
tamoxifen when response rates were assessed by mam-
mography (34 vs. 16%, respectively; P\0.001) and
ultrasound (35 vs. 25%, respectively; P = 0.042).
The proportion of patients able to undergo breast-con-
serving surgery was signiﬁcantly higher in the letrozole
group than in the tamoxifen group (45 vs. 35%, respec-
tively; P = 0.022). Of note, the odds ratio for breast-
conserving surgery was 4.56 (P = 0.0001) for patients
presenting with T2 tumors compared with all other T
stages. The only other factor that increased the odds of
undergoing breast-conserving surgery was treatment with
letrozole (odds ratio 1.71, P = 0.03).
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A supportive analysis of clinical efﬁcacy data conducted in
patients with centrally conﬁrmed ER+ or PgR+ tumors also
showed that outcomes were signiﬁcantly improved with
letrozole (n = 124) compared with tamoxifen (n = 126)
[37]. In this subgroup, the ORR was 60% for letrozole
versus 41% for tamoxifen (P = 0.004), and breast-con-
serving surgery was performed in 48 versus 36%,
respectively (P = 0.036).
There was a linear relationship between ER Allred
expression scores and response rates to both letrozole and
tamoxifen (see Fig. 2). Tumors with low ER expression
were still responsive to letrozole but not to tamoxifen [37].
Of note, letrozole response rates were numerically superior
to tamoxifen response rates in every ER Allred category
from three to eight, indicating that letrozole is more
effective than tamoxifen regardless of the level of ER
expression [37]. This ﬁnding is important, because of all
the AIs, only letrozole has demonstrated clear ORR supe-
riority over tamoxifen in ER-poor tumors. When the effects
of letrozole and anastrozole on tumors with low ER values
(Allred scores 2–5) were compared in the neoadjuvant
setting, only letrozole achieved a signiﬁcant reduction in
cell proliferation in ER-poor tumors [35].
Letrozole, but not tamoxifen, signiﬁcantly reduced the
expression of estrogen-regulated proteins PgR and TFF1
[38]. Average tumor PgR expression decreased dramati-
cally on letrozole treatment (P = 0.0001), and only 4.4% of
surgical specimens exhibited an Allred score of between
six and eight for PgR expression. The signiﬁcant decrease
in PgR expression with letrozole remained signiﬁcant in
the ER+, HER2+ subpopulation. In contrast, changes in
PgR expression with tamoxifen therapy were not consis-
tent, with both increases and decreases in expression
frequently observed in the overall and ER+, HER2+ sub-
populations. Analysis of changes in TFF1 produced similar
conclusions, with letrozole markedly reducing expression
(P = 0.0001) and tamoxifen producing no overall trend in
either direction.
HER1/HER2 and response
Approximately 15% of tumors were ER+ and overexpres-
sed both HER1 and HER2. The response rate in this patient
subgroup was signiﬁcantly higher with letrozole than with
tamoxifen (88 vs. 21%) [37]. The odds ratio for response to
letrozole versus tamoxifen was 28 (95% CI 4.5, 177;
P = 0.0004). Letrozole was equally effective for HER1/
HER2+ and HER1/HER2– tumors, whereas tamoxifen was
signiﬁcantly less effective in HER2+ compared with
HER2– tumors (P = 0.045). These data suggest that
although HER1 and HER2 status might not be the only
explanation for the superiority of letrozole over tamoxifen,
overcoming resistance pathways associated with HER1
and HER2 expression is a signiﬁcant component of the
improvement in outcomes associated with letrozole treat-
ment observed in this clinical trial. FISH analysis of tumor
samples conﬁrmed the clinical efﬁcacy of letrozole in
breast cancers with or without HER2 ampliﬁcation (ORR
71% in both subsets; P = 0.98). In contrast, tamoxifen-
treated tumors with HER2 gene ampliﬁcation had lower
clinical response rates than tamoxifen-treated HER2–
tumors (33 vs. 49%, P = 0.49) (see Table 2)[ 40].
Biomarkers of tumor proliferation
Letrozole inhibited tumor proliferation, measured by the
biomarker Ki67, to a greater extent than tamoxifen
(reduction in geometric mean Ki67 level 87 vs. 75%,
respectively; P = 0.0009). The differences in Ki67 reduc-
tion were also observed in ER+, HER1 and/or HER2
overexpressing tumors (88% for letrozole vs. 45% for
tamoxifen, respectively; P = 0.0018) [38]. Changes in the
percentage of Ki67-positive cells in HER1/2+ tumors
treated with letrozole or tamoxifen are shown in Fig. 3.
More recently, it was found that HER2 FISH-positive
tumors showed higher histologic grade (P = 0.009), higher
pretreatment Ki67 (P = 0.005), and less Ki67 suppression
after letrozole when compared with HER2 FISH-negative
tumors (P = 0.0001) [40]. Letrozole signiﬁcantly decreased
the geometric mean Ki67 level in HER2 FISH-negative
tumors (from 6.25 [95% CI 5.16, 7.58%] to 0.68% [95% CI
0.53, 0.87%]; P = 0.0001), but the decrease in HER2 FISH-
positive tumors was blunted (from 14.73 [95% CI 9.67,
Fig. 2 Clinical response rate versus estrogen receptor (ER) Allred
score for letrozole and tamoxifen. The P value for a linear logistic
model was 0.0013 for letrozole and 0.0061 for tamoxifen according
the Wald test. In this analysis, ER–, PgR+ cases (determined by
conventional cut points) were excluded. Reprinted from [37] with
permission from the American Society of Clinical Oncology
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A similar observation for Ki67 was made in a smaller cohort
of tamoxifen-treated tumors [40].
The relationship between cell cycle CR, deﬁned as £1%
of post-treatment Ki67 staining in the inﬁltrating compo-
nent of the tumor, and HER2 status of tumors treated with
Table 2 Analysis of clinical, ultrasound, and mammogram response data according to HER2 FISH status in letrozole-treated patients and
tamoxifen-treated patients
Response Category No. responses Total No. (%) No. responses Total No. (%)
HER2 FISH-positive Tamoxifen-treated patients HER2 FISH-negative Tamoxifen-treated patients P-value
a
Clinical 3 9 (33) 44 90 (49) 0.49
Ultrasound 3 9 (33) 26 74 (35) 0.99
Mammography 1 9 (11) 22 90 (24) 0.68
HER2 FISH-positive Letrozole-treated patients HER2 FISH-negative Letrozole-treated patients P-value
b
Clinical 12 17 (71) 131 185 (71) 0.98
Ultrasound 8 17 (47) 91 170 (54) 0.61
Mammography 7 16 (44) 84 178 (47) 0.79
Reprinted from [40] with permission from the American Society of Clinical Oncology
HER2 human epidermal growth factor receptor 2, FISH ﬂuorescence in situ hybridization
a Fisher test P-value
b Mantel–Haenzel P-value
Fig. 3 A box plot of before and
after treatment Ki67 values in
the estrogen-receptor-positive,
human epidermal growth factor
receptor (HER) 1/2+ subset.
With letrozole (n = 15), 11
showed a decrease, one
exhibited no change, and three
showed an increase, of which
only one was[2-fold
(0.1–0.3%). With tamoxifen
(n = 17), ten showed a decrease
and seven an increase, of which
three were relatively dramatic
(9.5–22.7, 20.9–40.7, and
0.1–17.3%). Reprinted from
[38] with permission from the
American Association for
Cancer Research
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FISH-negative than FISH-positive tumors met the deﬁni-
tion of a cell cycle CR at the time of surgery (60 vs. 12%;
P = 0.0001). There was a high level of correlation between
lack of cell cycle CR and the presence of a positive HER2
FISH test (P = 0.0001) for letrozole- and tamoxifen-treated
tumors, which is consistent with the conclusion that HER2
gene ampliﬁcation generates resistance at the level of cell
cycle progression regardless of which endocrine therapy is
used [40].
These biomarker ﬁndings are discordant with clinical
observations that tumor regression is unaffected by HER2
ampliﬁcation status in patients treated with neoadjuvant
letrozole and may imply therapeutic resistance that could
manifest later in the clinical course of the disease. Con-
sistent with this ﬁnding, Miller and colleagues also
reported that neoadjuvant letrozole produces rapid and
profound decreases in expression of Ki67 and PgR that do
not always correlate with clinical and pathological
responses [47].
Gene expression proﬁling
Preliminary gene expression proﬁling analysis of biopsies
taken pretreatment and 1 month post letrozole treatment
showed down-regulation of genes involved in DNA repli-
cation and synthesis, cell cycle progression, apoptosis
suppression, and tissue invasion [39]. These results illus-
trate the molecular basis for estrogen-deprivation letrozole
therapy which may be useful in the development of pre-
dictive models of ER+ breast cancer.
Aromatase
Sufﬁcient pre- and post-treatment tumor material was
available from 171 cases (81 on letrozole and 90 on
tamoxifen) from the P024 trial for immunohistochemistry
analysis of aromatase protein expression [41]. Aromatase
was detected in all tumor compartments, with the strongest
staining observed in malignant epithelial cells. Median
aromatase values did not change signiﬁcantly with letroz-
ole or tamoxifen treatment; however, changes in score did
occur in individual cases, with more noticeable effects
observed in letrozole-treated patients [41]. A positive
correlation existed between baseline ER and aromatase
staining in cancer cells, while a negative correlation was
observed between baseline Ki67 and aromatase expression
in cancer plus stroma. Baseline aromatase expression did
not predict response to letrozole or tamoxifen, or changes
in Ki67 induced by treatment. However, negative staining
in both stroma and cancer after treatment was strongly
associated with fewer cell cycle CR and smaller Ki67
declines with letrozole (but not tamoxifen) treatment [48].
Safety and duration of therapy
P024 demonstrated that letrozole is well-tolerated in the
neoadjuvant setting [21]. There were no major tolerability
differences between letrozole and tamoxifen, and adverse
effects of a similar nature were seen in 57% of patients in
each arm [21]. The most common treatment-related
adverse event was hot ﬂushes, occurring in 20% of patients
in the letrozole group and 24% of patients in the tamoxifen
group.
The excellent tolerability, predictable pharmacokinetics,
and minimal drug–drug interactions [49, 50] make letroz-
ole a particularly suitable option for older women unable to
tolerate or unwilling to accept neoadjuvant chemotherapy
and in whom the presence of comorbidities and use of
concomitant therapies complicate treatment selection [20].
The median age of patients in P024 treated with letrozole
was 68 years, and 46% of patients were at least 70 years
old. The feasibility and safety of letrozole was also
reported recently from another trial using letrozole as pri-
mary systemic therapy in elderly patients (median age
79 years) with breast cancer [51]. In addition, letrozole has
been successfully administered to elderly patients (median
age of the elderly subgroup 75 years; range 70–96 years) in
the advanced breast cancer setting [52].
The favorable safety proﬁle of letrozole also allows for
the extension of the neoadjuvant treatment beyond the
4 months used in the P024 trial. In a recent study, 33
postmenopausal women with HR+ breast cancer ineligible
for breast-conserving surgery were treated with letrozole
for 4 months. Continued administration of letrozole for a
further 4 months in responders and patients with stable
disease resulted in a statistically signiﬁcant improvement in
tumor size reduction (P = 0.039); ORR was 90% in
patients receiving preoperative treatment for longer than
4 months compared with 57% in patients receiving treat-
ment up to 4 months [53].
In another study, 42 patients who were unsuitable for
breast-conserving surgery or had refused surgery after
responding to initial neoadjuvant therapy with letrozole for
3 months beneﬁted from continuing tumor volume reduc-
tion during further letrozole treatment administered for up
to 12 months [54]. The median reductions in tumor volume
were 52% (95% CI 37, 62) from 0 to 3 months, 57%
(95% CI 26, 100) from 3 to 6 months, and 66% (95% CI
22, 100) from 6 to 12 months. Extending the duration of
letrozole also improved the CR rate, which increased from
4/42 patients (9.5%) at 3 months to 12/42 (29%) by
6 months and 8/22 (36%) by 12 months.
Breast Cancer Res Treat (2007) 105:33–43 39
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Neoadjuvant therapy with AIs is a safe and effective
treatment option for postmenopausal women who are
unwilling or unable to undergo surgery or preoperative
chemotherapy [21, 22, 55–57]. Letrozole is signiﬁcantly
more effective than tamoxifen in the neoadjuvant setting in
terms of ORR and increased rate of breast-conserving
surgery [21, 55].
One of the advantages of using a neoadjuvant strategy is
the opportunity to gain information on tumor response
early in the course of treatment. Detailed studies correlat-
ing clinical response to neoadjuvant therapy with changes
in tumor biomarkers and gene expression may ultimately
prove useful to tailor therapy for individual patients and to
gain a better understanding of the biology of HR+ breast
cancer. Correlative studies conducted using tumor samples
from P024 have revealed important information about how
breast tumors respond to letrozole [37–40]. Letrozole was
shown to be signiﬁcantly more effective than tamoxifen in
the inhibition of ER+ tumor proliferation, since letrozole
produced a greater reduction in levels of the proliferation
biomarker Ki67 [38]. It has been suggested that a greater
suppression in proliferation could lead to greater long-term
survival in the adjuvant setting. Preliminary data from the
Immediate Preoperative Anastrozole Tamoxifen or Com-
bined with Tamoxifen trial have indicated that short-term
changes in Ki67 levels, after 2 and 12 weeks, may be a
useful predictive marker for relapse-free survival in
patients treated with neoadjuvant AI therapy [58]. It has
also been suggested that changes in proliferation and
concurrent changes in apoptosis may be expected to be
more predictive of adjuvant beneﬁt from endocrine therapy
than clinical response [59].
Correlative studies have also highlighted the complexity
of breast cancer biology and revealed discordance between
clinical and biomarker responses [40]. Ampliﬁcation of
HER2 was shown to be associated with a more aggressive
breast cancer phenotype and greater resistance to tamoxi-
fen [37, 40]. Clinical response data from the P024 trial
have shown that letrozole is equally effective in HER2+
and HER2– tumors, whereas tamoxifen is less effective in
HER2+ tumors [37]. These data suggest that letrozole
could be a superior option to tamoxifen for postmenopausal
women with HER2+, HR+ tumors [37]. However, analysis
of proliferation markers has provided evidence of estrogen-
independent proliferation of ER+, HER2+ breast cancer
despite neoadjuvant letrozole [40]. It appears that cell-
cycle regulation is partially or completely estrogen-inde-
pendent in the majority of primary tumors showing HER2
gene ampliﬁcation, and patients with such tumors may
eventually develop resistance to adjuvant AI therapy.
Novel strategies to delay or overcome hormone resistance
are described elsewhere in this supplement, in the article,
‘‘Femara and the future.’’
Gene expression proﬁling has demonstrated that letroz-
ole targets genes responsible for DNA replication and
synthesis, cell cycle progression, apoptosis, and tissue
invasion [39]. Research into genetic proﬁling is continuing,
with the aim of developing clinically relevant predictive
models that can accurately classify ER+ disease according
to likely response to speciﬁc neoadjuvant therapies. Pre-
dictive models will improve treatment individualization
and help to avoid unnecessary treatment-related toxicity in
patients unlikely to beneﬁt from systemic therapies [17,
60].
The P024 trial has clearly demonstrated the therapeutic
superiority of letrozole over tamoxifen for the neoadjuvant
management of primary breast cancer. The trial has also
provided the oncology community with a validated
research setting within which to gain valuable insights into
the molecular features of ER+ breast cancer and its treat-
ment that will help shape new therapies in the years to
come.
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